p53 gene product and EGF-receptor are highly expressed in placental site trophoblastic tumor

Human Pathology

Volumn 28, Issue 11, 1997, Pages 1302-1306

  Müller Höcker, Josef ^a   Obernitz, Nikolaus ^b   Johannes, Axel ^b   Löhrs, Udo ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

bc12 immunohistochemistry; EGF R; Ki 67 (MIB 1); p53; Placental site trophoblastic tumor

Indexed keywords

CHORIONIC GONADOTROPIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; CASE REPORT; CYTOTROPHOBLAST; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; TROPHOBLASTIC TUMOR; TUMOR SUPPRESSOR GENE;

EID: 0030832762     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(97)90206-9     Document Type: Article

References (39)

1. Kurman RJ, Scully RE, Norris HJ: Trophoblastic pseudotumor of the uterus: An exaggerated form of "syncytial endometritis" simulating a malignant tumor. Cancer 38:1214-1226, 1976
2. Kurman RJ: The morphology, biology, and pathology of intermediate trophoblasts - A look back to the present. HUM PATHOL 22:847-855, 1991
3. Silverberg SG, Kurman RJ: Tumors of the uterine corpus and gestational trophoblastic disease. Atlas of tumor pathology, 3rd series, fascicle 3. Washington DC, Armed Forces Institute of Pathology
4. Young RE, Kurman RJ, Scully RE: Prolifcrations and tumors of intermcdiate throphoblast of the placental site. Semin Diagn Pathol 5:223-237, 1988
5. King LA, Okagaki T, Twiggs LB: Resolution of pulmonary metastases with chemotherapy in a patient with a placental site trophoblastic tumor. Int J Gynecol Cancer 2:328-331, 1992
6. Kurman RJ, Main CS, Chen HC: Intermediate trophoblast: A distinctive form of trophoblast with specific morphological, biochemical and functional features. Placenta 5:349-369, 1984
7. Fukunaga M, Ushigome S: Malignant trophoblastic tumors: Immunohistochemical and flow cytometric comparison of choriocarcinoma and placental site trophoblastic tumors. HUM PATHOL 24:1098-1106, 1993
8. Gerdes J, Li L, Schlueter C, et al: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:867-873, 1991
9. Piris MA, Pezella F, Martinez-Montero JC, et al: p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. Br J Cancer 69:337-341, 1994
10. Nakamura S, Akazawa K, Kinukawa N, et al: Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma. HUM PATHOL 27:225-233, 1996
11. Shimaya K, Shiozaki H, Inoue M, et al: Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma. Virhows Arch (A) 422:271-276, 1993
12. Bosari S, Viale G, Radaelli U, et al: p53 Accumulation in ovarian carcinoma and its prognostic implications. HUM PATHOL 24:1175-1179, 1993
13. Silvestrini R, Veneroni S, Daidone MG, et al: The BCI-2-protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504, 1994
14. Quinlan DC, Davidson AG, Summers CL, et al: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828-4831, 1992
15. Brambilla E, Gazzeri S, Moro D, et al: Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143:199-210, 1993
16. DiGiuseppe JA, Hruban RH, Goodman SN, et al: Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 101:684-688, 1994
17. Battifora H: p53 immunohistochemistry: A word of caution. HUM PATHOL 25:435-437, 1994
18. Campo E, Calle-Martin O, Miquel R, et al: Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinoma. Cancer Res 51:4436-4442, 1991
19. Resnick M, Lester S, Tate JE, et al: Viral and histopathologic correlates of MN and MIB-1 expression in cervical intraepithelial neoplasia. HUM PATHOL 27:234-239, 1996
20. Pezella F, Morrison H, Jones M, et al: Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 22:39-44, 1993
21. Leek RD, Kaklamanis L, Pezella F, et al: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69:1351-139, 1994
22. Diebold J, Baretton G, Felchner M, et al: bcl-2-expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 105:341-349, 1996
23. Yonish-Rouach E, Resnitzky D, Lotem J, et al: Wild-type p53 induced apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347, 1991
24. Vaux DL, Cory S, Adams JM: Bcl-2gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B-cells. Nature 335:440-442, 1988
25. Hockenbery D, Nunez G, Milliman C, et al: bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990
26. Allred DC, Clar GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
27. Cesarman E, Inghirami G, Chadburn A, et al: High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 143:845-856, 1993
28. Pezella F, Tse AGD, Cordell JL, et al: Expression of the bcl-2 oncogene protein is not specific for the 14; 18 chromosomal translocation. Am J Pathol 137:225-232, 1990
29. Isaacson PG, Wotherspoon AC, Diss TC, et al: bcl-2 expression in lymphomas. Lancet 337:175-176, 1991
30. Derynck R, Goeddel DV, Ullrich A, et al: Synthesis of messenger RNAs for transforming growth factor α and β and the epidermal growth factor receptor by human tumors. Cancer Res 47:702-712, 1987
31. Di Marco E, Pierce JH, Fleming YP, et al: Autocrine interaction between TGF-α and the EGF-receptor: Quantitative requirements for induction of the malignant phenotype. Oncogene 4:831-838, 1989
32. Umekita Y, Enokizono N, Sagara Y, et al: Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-α) in human breast cancer: Their relationship to estrogen receptor status, histological grade, mitotic index and nodal status. Virchows Arch [A] 420:345-351, 1992
33. Carpenter G: Epidermal growth factor. Handbk Exp Pharmacol 57:90-126, 1981
34. Hofmann GE, Scott RT, Jr, Bergh PA, et al: Immunohistochemical localization of epidermal growth factor in human endometrium, decidua, and placenta. J Clin Endocrinol Metab 73:82-87, 1991
35. Beruchuck A, Soisson AP, Olt GJ, et al: Epidermal growth factor receptor expression in normal and malignant endometrium. Am J Obset Gynecol 161:1247-1252, 1989
36. Nyholm HCJ, Nielsen AL, Ottesen B: Expression of epidermal growth factor receptors in human endometrial carcinoma. Int J Gynecol Pathol 12:241-245, 1993
37. Nikura H, Sasano H, Kaga K, et al: Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium. HUM PATHOL 27:282-289, 1996
38. Khalifa MA, Abdoh AA, Mannel RS, et al: Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer 73:370-376, 1994
39. Wang DP, Konishi I, Koshiyama M et al: Expression of c-erb b-2 protein and epidermal growth factor receptor in endometrial carcinomas. Cancer 72:2628-2637, 1993